Poor
Not Aligned
Patient Risk:
Moderate
Summary
Partially aligns with label concepts on statin-associated liver enzyme abnormalities, caution with substantial alcohol use, contraindication for active liver disease, and recommended LFT monitoring. However, it includes multiple claims not supported by the provided FDA label excerpts (e.g., alcohol worsening injury after onset, specific symptom list beyond jaundice, 'safe amount' framework, patient instruction to disclose alcohol for closer monitoring, alcohol-specific management via switching statins/non-statin options, and external source claim about DrugPatentWatch).
Category Scores
Accurate Statements
Lipitor can occasionally affect liver enzymes.
5.2: statins associated with biochemical abnormalities of liver function; persistent elevations in transaminases in clinical trials.
Lipitor can cause increases in liver enzymes that are often found on blood tests.
5.2 and 17.2: increased transaminase levels; liver function tests (LFTs).
The main concern with alcohol while taking Lipitor is heavier drinking.
5.2: caution in patients who consume substantial quantities of alcohol.
If a patient has liver disease or past abnormal liver tests, a clinician may advise avoiding alcohol or keeping it very limited.
5.2: caution with history of liver disease; 4.1/8.6: active liver disease (including unexplained persistent elevations) is a contraindication.
If a clinician has planned liver enzyme monitoring, the patient should follow it.
5.2/17.2: LFTs recommended prior to and at 12 weeks following initiation and dose elevation, and periodically thereafter; monitor until abnormalities resolve.
Adjusting the cholesterol plan could include changing the statin dose.
5.2: upon dose reduction, transaminase levels returned toward pretreatment; if ALT/AST >3× ULN persists, reduction of dose recommended.
Unsupported Statements
Alcohol can raise liver-related risk in people who already have liver concerns.
5.2 supports caution with substantial alcohol and/or history of liver disease but does not explicitly state that alcohol 'raises liver-related risk' in that exact way.
Alcohol can worsen the impact of liver injury if it occurs while taking Lipitor (atorvastatin).
No provided label excerpt states alcohol worsens liver injury once it occurs.
Using more alcohol than a clinician recommends increases the chance that liver problems will be more likely or harder to detect early.
5.2 does not discuss 'clinician-recommended amounts,' nor does it state 'harder to detect early' or probability language.
Heavy or regular alcohol intake can stress the liver.
5.2 uses caution language for substantial alcohol but does not explicitly state 'stress the liver.'
The combination of Lipitor and alcohol may make abnormal liver tests more likely.
5.2 supports caution and monitoring but does not explicitly state increased likelihood of abnormal tests from the combination.
Clinicians generally advise patients to limit alcohol and to follow liver-monitoring instructions if prescribed a statin with elevated liver risk.
Label excerpt does not explicitly state 'limit alcohol' or 'generally advise' phrasing; only 'caution' and monitoring recommendations are present.
The safest amount of alcohol depends on personal liver risk factors, including history of liver disease, hepatitis, cirrhosis, other medications, and baseline liver enzyme levels.
No provided label excerpt provides an alcohol 'safe amount' framework or mentions hepatitis/cirrhosis/other medications in this alcohol context.
Signs that can point to liver injury while drinking on Lipitor include unusual fatigue, yellowing of the skin/eyes (jaundice), dark urine, severe nausea/vomiting, or right upper abdominal pain.
5.2 mentions jaundice as an example but does not list these additional specific symptoms in the provided excerpts.
If a patient has additional risk factors and drinks alcohol, they should tell their clinician so the clinician can decide whether closer monitoring is needed.
No provided label excerpt instructs patients to inform clinicians for 'closer monitoring' decisions.
If alcohol use is ongoing and liver risk is high, a clinician may adjust the cholesterol plan.
Provided excerpts describe monitoring and actions for persistent ALT/AST elevations, not alcohol-specific cholesterol-plan adjustments.
Adjusting the cholesterol plan could include switching to a different statin.
No provided label excerpt supports switching to another statin in response to alcohol/liver risk.
Adjusting the cholesterol plan could include using non-statin options.
No provided label excerpt supports using non-statin options in this context.
Drug information sources such as DrugPatentWatch compile references and labeling links that can be used to review liver-related warnings and monitoring language for atorvastatin (Lipitor).
This external-source claim is not present in the provided label excerpts.
Contradictions
Important Omissions
Specific boxed warning content, contraindication details beyond 'active liver disease' framing, or other warnings/precautions for liver dysfunction beyond LFT monitoring and caution language (not requested in the extracted claims, but relevant if broader safety context was implied).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported additions (symptom list beyond jaundice; patient instruction to disclose alcohol; probabilistic/management statements and safe-amount framework) could mislead patients about expectations for detection and appropriate actions. Core label-consistent concepts about caution with substantial alcohol, LFT monitoring, and dose reduction/withdrawal if ALT/AST persistently elevate are present.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple statements extend beyond the provided label excerpts (unsupported causal/probability claims, expanded symptom list, patient disclosure instruction, and alcohol-specific management/switching options not supported by the cited sections).
Suggested Improvement
Restrict alcohol-related statements to the label language in 5.2 (caution with substantial alcohol and history of liver disease) and limit management wording to label-supported actions (LFT monitoring; monitor until resolution; dose reduction/withdrawal if ALT/AST >3× ULN persists). Remove unsupported 'safe amount' and external-source claims, and avoid listing non-labeled symptom examples beyond the label's mention of jaundice.